Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.Webcast: https://bioarctic.events.inderes.com/q1-report-2025/register  If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast:https://bioarctic.events.inderes.com/q1-report-2025/register   If you wish to participate via teleconference, please register on the link below. After registration...

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.
Webcast: https://bioarctic.events.inderes.com/q1-report-2025/register 

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/bioarctic/q1-report-2025/dial-in 

The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.com/en/investors/financial-reports-and-presentations/ after the presentation.

---

For more information, please contact:
Anders Martin-Löf, CFO 
Phone: +46 70 683 79 77 
E-mail: [email protected] 

This information was submitted for publication at 08:30 a.m. CET on May 13, 2025.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/invitation-to-presentation-of-bioarctic-s-first-quarter-report-for-january---march-2025-on-may-21-at,c4148987

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-bioarctics-first-quarter-report-for-january---march-2025-on-may-21-at-9-30-am-cet-302453517.html